4.5 Article

Net costs of dementia by disease stage

Journal

ACTA PSYCHIATRICA SCANDINAVICA
Volume 124, Issue 5, Pages 384-395

Publisher

WILEY
DOI: 10.1111/j.1600-0447.2011.01741.x

Keywords

dementia; Alzheimer disease; cost of illness; family caregivers

Categories

Funding

  1. German Research Network on Dementia (KND)
  2. German Research Network on Degenerative Dementia (KNDD)
  3. German Federal Ministry of Education and Research [KND: 01GI0102, 01GI0420, 01GI0422, 01GI0423, 01GI0429, 01GI0431, 01GI0433, 01GI0434, KNDD: 01GI0710, 01GI0711, 01GI0712, 01GI0713, 01GI0714, 01GI0715, 01GI0716]
  4. AstraZeneca
  5. Bayer Vital
  6. Bohringer-Ingelheim
  7. Bristol-Myers Squibb
  8. Eli Lilly
  9. General Electrics
  10. Janssen-Cilag
  11. Lundbeck
  12. Merck
  13. Merz
  14. Novartis
  15. Pfizer
  16. Sanofi-Aventis
  17. Schering

Ask authors/readers for more resources

Objective: To estimate net costs of dementia by degree of severity from a societal perspective, including a detailed assessment of costs of formal and informal nursing care. Method: In a cross-sectional study, costs of illness were analysed in 176 dementia patients and 173 matched non-demented control subjects. Healthcare resource use and costs were assessed retrospectively by means of a questionnaire. Dementia patients were classified into three disease stages, and linear regression models were applied to estimate net costs of dementia by degree of severity. Results: Annual net costs of dementia by stage were approximately (sic)15 000 (mild), (sic)32 000 (moderate) and (sic)42 000 (severe), corresponding to US-$21 450, 45 760 and 60 060 respectively. Across disease stages, nursing care accounted for approximately three-quarters of total costs, of which half resulted from informal care. In sensitivity analyses using different valuation methods for nursing care, total costs decreased or increased by more than 20%. Conclusion: Net costs more than double across stages of dementia. Informal care accounts for a considerable share of nursing care costs, and the approach to valuation of informal care has a large impact on cost-of-illness estimates.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available